UPF 1069

Research use only, not for human use.

UPF 1069 is a specific PARP2 inhibitor ( IC50: 0.3 μM). It is ~27-fold selective against PARP1.

UPF-1069 is a selective and potent PARP2 inhibitor. UPF-1069 induces apoptosis. UPF-1069 shows neuroprotective and anti-ischemic effects in vivo.

UPF 1069 (Compound 55) is a PARP inhibitor, with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively. UPF 1069 (1 μM) reduces the residual PARP activity by approximately 80% of PARP-1-deficient fibroblasts, but only slightly inhibits the enzymic activity in wild-type fibroblasts. UPF 1069 (0.1-1 μM) markedly enhances CA1 hippocampal damage. UPF 1069 (10 μM) also exacerbates oxygen-glucose deprivation (OGD) damage in organotypic hippocampal slices. However, UPF 1069 alleviates the damage cuased by OGD in mixed cortical cell cultures, shows a potent neuroprotective activity both at a concentration (1 μM) selectively acting on PARP-2 and at a concentration (10 μM) inhibiting both PARP-1 and PARP-2 activities.

——

UPF-1069, UPF1069, UPF 1069

Others

Other Targets

PARP1| PARP2

Cancer

——

1048371-03-4

279.29

C17H13NO3

>98% (HPLC)

DMSO : ≥ 100 mg/mL 358.05 mM

c1(=O)[nH]ccc2c(cccc12)OCC(=O)c1ccccc1

5-(2-oxo-2-phenylethoxy)isoquinolin-1(2H)-one

(-20℃)

With Ice Pack

≥ 2 years